CTLA4 and gastric cancer: The phase I/II CheckMate-032 trial assessed the efficacy and safety of anti-PD-1 Ab nivolumab monotherapy or two different schedules of nivolumab plus anti-CTLA-4 Ab ipilimumab in patients with chemotherapy-refractory GC [14].